Palmitoylethanolamide in glaucoma, retinoprotection and improving ou

Recent studies show that administration of PEA in glaucoma patients has a double effect, decrease the IOP and neuroprotection. The IOP is the major risk factor in glaucoma, constricts blood vessels and reduces the delivery of oxygen and nutrients to the retina and optic nerve (ON), causing a process of ischemia and cell death (apoptosis).
New research points out palmitoylethanolamide has a dual action in glaucoma:

1. It reduces high eye pressure by promoting fluid flow out of the eye, and

2. PEA protects nerve cells and retina cells via its neuroprotective and reparative properties.

In the Youtube the essence of the natural treatment of glaucoma with palmitoylethanolamide has been summarized. Daily dose: 2-3 times 400 mg palmitoylethanolamide. Literature on this topic on http://palmitoylethanolamide4pain.com/2015/02/20/youtube-on-palmitoylethanolamide-as-a-natural-treatment-for-glaucoma/